
Mark Garzotto, MD, discusses phase 3 data on aglatimagene besadenovec plus standard-of-care external beam radiation therapy with or without short-course androgen deprivation therapy in localized prostate cancer.

Mark Garzotto, MD, discusses phase 3 data on aglatimagene besadenovec plus standard-of-care external beam radiation therapy with or without short-course androgen deprivation therapy in localized prostate cancer.